Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS
The Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis (SPMS) did not achieve its primary and secondary endpoints, Biogen (NASDAQ: BIIB) reported today. During the study, natalizumab was generally well tolerated and adverse events were consistent with its known safety profile.
ASCEND evaluated the efficacy and safety of natalizumab to slow the accumulation of disability progression unrelated to relapse in SPMS patients, an unmet medical need. The majority of study participants had EDSS scores of 6.0 to 6.5 (walking aid required) and were non-relapsing for two years prior to enrollment in the study. The study’s composite primary endpoint evaluated the percentage of patients whose disability had progressed on one or more of three disability measurements comprising the composite endpoint.
Natalizumab demonstrated a statistically significant effect on upper limb function (one of the three components of the primary composite endpoint) unrelated to relapses. Consistent with the established effects of natalizumab in relapsing multiple sclerosis, analyses of exploratory endpoints suggest that some patients received a benefit from treatment, including reduction of relapses and new MRI lesions.
“While we’re disappointed with these results, we believe this research will provide the MS community important insights into this more advanced patient population, and the benefits that natalizumab may provide in areas such as upper limb function,” said Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer at Biogen. “Given the challenges of treating this advanced stage of MS, these results underscore the importance of treatment early in the course of disease with effective disease-modifying therapies before a patient advances to SPMS.”
SPMS is characterized by ongoing nerve damage or loss and patients experience disability progression with increasingly less frequent relapses. Despite extensive clinical research, treatment options for patients with SPMS are extremely limited and none have demonstrated efficacy in slowing the progression of disability unrelated to relapse.
Natalizumab is a high-efficacy treatment for patients with relapsing forms of MS, including relapsing-remitting MS. The safety and efficacy of natalizumab has been established across a robust clinical program and real-world use with more than a decade of clinical experience demonstrating its benefits on disease progression and sustained efficacy in relapsing MS with a well-characterized safety profile.
Detailed results from ASCEND will be presented at a future medical conference.
ASCEND (A Study to Characterize the Efficacy of Natalizumab on Disability in SPMS) was a randomized, double-blind, placebo-controlled, Phase 3 trial involving 889 patients in 15 countries. Participants were randomized to receive either natalizumab 300 mg or placebo intravenously every four weeks for 96 weeks.
The primary endpoint of the study was the percentage of patients with confirmed progression of disability on one or more components of ASCEND’s composite endpoint: the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW) and the 9-Hole Peg Test (9HPT) where progression was confirmed at a second visit at least 6 months later and at week 96.
About TYSABRI ® (natalizumab)
TYSABRI is a DMT approved in more than 65 countries. In the United States, TYSABRI is indicated as monotherapy for the treatment of patients with relapsing forms of MS. In the European Union, it is indicated as a single DMT in highly active relapsing-remitting MS for adult patients who have high disease activity despite treatment with a beta interferon or glatiramer acetate or patients with rapidly evolving severe RRMS.
TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain which usually leads to death or severe disability. Risk factors that increase the risk of PML are presence of anti-JCV antibodies, prior immunosuppressant use, and longer TYSABRI treatment duration. Patients who have all three risk factors have the highest risk of developing PML. TYSABRI increases the risk of developing encephalitis and meningitis caused by herpes simplex and varicella zoster viruses. Serious, life-threatening, and sometimes fatal cases have been reported in the postmarketing setting in multiple sclerosis patients receiving TYSABRI. Clinically significant liver injury has also been reported in the post-marketing setting.
Other serious adverse events that have occurred in TYSABRI-treated patients include hypersensitivity reactions (e.g., anaphylaxis) and infections, including opportunistic and other atypical infections.
TYSABRI has advanced the treatment of MS patients with its proven ability to slow the progression of disability, reduce relapse rates, and impact the number of MRI brain lesions with a well-characterized safety profile. Data from the Phase 3 AFFIRM trial, which was published in the New England Journal of Medicine, showed that at two years, TYSABRI treatment led to a 67 percent relative reduction (p<0.001) in the annualized relapse rate when compared with placebo and reduced the relative risk of disability progression by 42 percent (p<0.001).
TYSABRI is a monoclonal antibody that selectively binds to α4-integrin and is thought to interrupt the activity of inflammatory cells in MS patients by blocking the interaction between α4β1-integrin and vascular cell adhesion molecule-1. Disruption of these molecular interactions prevents transmigration of leukocytes across the endothelium into inflamed parenchymal tissue. The specific mechanism(s) by which TYSABRI exerts its effects in multiple sclerosis have not been fully defined.
For additional important safety information, and the United States full prescribing information, please visit www.TYSABRI.com or your respective country’s website.
Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the company, please visit www.biogen.com.
This press release contains forward-looking statements, including statements about potential insights into treatments for SPMS. These statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will" and similar expressions, and are based on the company’s current beliefs and expectations. Drug development involves a high degree of risk, and only a small number of research and development programs results in the commercialization of a product or additional product indications. Success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. For more detailed information on the risks and uncertainties associated with Biogen's drug development activities, please review the Risk Factors section of Biogen's most recent annual or quarterly report filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCL Technologies Named Top Employer 2022 in 17 Countries Globally20.1.2022 20:00:00 CET | Press release
HCL Technologies (HCL), a leading global technology company, has been named a Top Employer in 17 countries by Top Employers Institute, a global authority in recognizing excellence in people practices. HCL emerged as a Top Employer, among some of the world’s largest and best-known enterprises, based on its dedication to fostering employee growth while continuing to drive value for clients around the globe. HCL has been awarded this status in Australia, Brazil, Canada, France, Germany, Guatemala, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, Poland, Singapore, South Africa, Sweden, the United Kingdom and the United States. Recognized for the sixteenth time in a row in the United Kingdom, HCL is also ranked first in Poland, Sweden and the Philippines. Each year, Top Employers Institute certifies organizations that are focused on putting their people first through their exceptional HR policies. The Top Employers Institute program certifies organizations based on the part
MPEG LA Offers One-Stop License for ATSC 3.020.1.2022 17:50:00 CET | Press release
MPEG LA, LLC today announced the availability of the ATSC 3.0 Patent Portfolio License (“ATSC 3.0 License” or “License”), providing one-stop access to patents that are essential to the next generation broadcast standard developed by the Advanced Television Systems Committee (ATSC). ATSC 3.0, already available in South Korea and many U.S. television markets, improves the television viewing experience with higher audio and video quality, improved compression efficiency, robust transmission for reception on fixed digital televisions and converter boxes as well as mobile devices, and enhanced accessibility, personalization, interactivity, and advanced emergency alert service capability. “MPEG LA is proud to continue its role in support of the broadcast industry’s next generation terrestrial broadcast system that began with our licenses for the ATSC 1.0 standard and the MPEG-2 video compression standard used in ATSC 1.0,” said MPEG LA President and CEO Larry Horn. “As a convenience to ATSC
Xylem Clocks 113,000 Volunteer Hours in 2021, Doubling Time Donated to Help Tackle Water Challenges in 55 Countries20.1.2022 16:30:00 CET | Press release
Global water technology company, Xylem (NYSE:XYL), announced today that almost 80 percent of its 16,000 employees volunteered their time to help solve urgent water challenges in 2021. Xylem’s global team collectively donated 113,000 hours in their communities, across 55 countries. The commitment of volunteer hours doubled from 2020 to 2021, despite the challenges of COVID-19. Xylem employees stepped up both in person, in their own communities, and virtually, finding new ways to make a difference. Initiatives included cleaning up waterways, supporting disaster response teams, and providing water education. "Volunteering is one way we invest in our mission to solve the world’s biggest water challenges,” said Austin Alexander, Vice President of Sustainability and Social Impact at Xylem. “Our colleagues, customers and NGO partners showed real passion, last year – doubling the number of hours they volunteered, compared with 2020. It was particularly encouraging to see this uplift in the fac
Kayrros Names Mark Taylor Vice President, Energy Transition20.1.2022 15:37:00 CET | Press release
Kayrros today announced the appointment of Mark Taylor as Vice President, Energy Transition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220120005515/en/ Mark Taylor, Kayrros Vice President, Energy Transition (Photo: Business Wire) In this new function, Mark will develop and execute the strategy to integrate Kayrros content, data and tools into the workflows of financial and industry professionals. He is based in London. Mark Taylor joins Kayrros from BloombergNEF, the research division of Bloomberg focused on energy, commodities, and climate, where he was head of product and host of the podcast, Switched On. In announcing the appointment, Kayrros President Antoine Rostand said: “Kayrros technological advances in asset observation are generating immense quantities of data that can help the world monitor progress toward Net Zero, reduce the climate footprint, optimize industrial operations and manage climate and transition
Diligent Boards Integrates with Microsoft Teams to Drive Secure and Strategic Collaboration in Board Meetings20.1.2022 15:00:00 CET | Press release
Diligent, a global leader in modern governance providing SaaS solutions across governance, risk, compliance and ESG, today announces the integration of Diligent Boards with Microsoft Teams. Customers can now use Diligent’s board governance software while using Teams, driving better decision-making by providing organizations with a secure way to access critical governance intelligence and meeting resources. “The pandemic has triggered a global shift in the way we work, and many organizations have permanently transitioned to virtual or hybrid working models,” said Ricardo Moreno, Senior Vice President, Worldwide Partnerships at Diligent. “Boards and executives need secure solutions to improve collaboration, workflows and communication within virtual meetings, all while driving better decision-making with curated data and intelligence. Diligent Boards’ integration with Microsoft Teams makes Diligent’s board leadership software more accessible than ever, driving more effective, collaborati
ProAmpac Announces New Active and Intelligent Packaging Partnership with Rutgers University Professor20.1.2022 15:00:00 CET | Press release
ProAmpac, a leader in flexible packaging and material science, has partnered with Rutgers University Department of Food Science professor, Dr. Kit Yam. This partnership is being integrated with ProAmpac’s Material Science and Innovation teams to support the company’s commitment to developing active and intelligent food packaging. “Dr. Yam is recognized as an expert in the fields of active and intelligent packaging and ProAmpac is honored to include him and his lab in our expanded research and development partnerships,” said Hesam Tabatabaei, global vice president of product development and innovation. “We are certain this partnership will accelerate innovation in smart packaging leading to food-safety solutions for consumers and extend shelf-life to reduce overall food waste.” Through this partnership, Dr. Yam’s lab will provide testing capabilities critical to ProAmpac’s smart packaging development mission. Dr. Yam states, “ProAmpac’s commitment to studying the fundamentals of active
Mavenir Brings Dynamic Network Slicing Innovation Through TM Forum Catalyst Ecosoft eHealth Program20.1.2022 15:00:00 CET | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced successful completion of dynamic network slicing and fulfillment as part of recently concluded 2021 TM Forum “Ecosoft eHealth” Catalyst program, that brings innovative solutions to important industry challenges. This Catalyst will enable service delivery to medical facilities internationally via 5G slices and will address artificial intelligence (AI), virtual reality (VR) and the use of virtual intelligent counselling agents (VICA) in use cases including surgeries and remote patient care. To carry these out, 5G networks offering low latency and high performance are crucial in surgeries and remote patient care. The “Ecosoft eHealth” Catalyst project which was demonstrated in collaboration with Orange, TIM, NTT, and other vendors, was focused on adopting dynamic network slicing and advanced service assurance ca